Cargando…

Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study

BACKGROUND: This post-hoc analysis of PsABio (NCT02627768) evaluated safety, effectiveness and treatment persistence in patients < 60 and ≥ 60 years of age receiving ustekinumab over 3 years. METHODS: Measures included adverse events (AE), clinical Disease Activity Index for Psoriatic Arthritis (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gossec, Laure, Theander, Elke, Chakravarty, Soumya D., Bergmans, Paul, Lavie, Frederic, Noël, Wim, Sharaf, Mohamed, Siebert, Stefan, Smolen, Josef S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251537/ https://www.ncbi.nlm.nih.gov/pubmed/37296456 http://dx.doi.org/10.1186/s13075-023-03078-8

Ejemplares similares

Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study
por: Gossec, Laure, et al.
Publicado: (2023)

Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results
por: Smolen, Josef S, et al.
Publicado: (2021)

Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study
por: Gossec, Laure, et al.
Publicado: (2023)

Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study
por: Gossec, Laure, et al.
Publicado: (2022)

Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data
por: Van Kuijk, Arno W R, et al.
Publicado: (2023)

PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis
por: Siebert, Stefan, et al.
Publicado: (2022)

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
por: Coates, Laura C, et al.
Publicado: (2022)

Ustekinumab for the treatment of psoriatic arthritis: an update
por: Davari, Parastoo, et al.
Publicado: (2014)

Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015)

Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study
por: Schett, Georg, et al.
Publicado: (2023)

Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study
por: Schett, Georg, et al.
Publicado: (2023)

Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
por: Ghosh, Subrata, et al.
Publicado: (2019)

Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
por: Ghosh, Subrata, et al.
Publicado: (2019)

Plant Abio-Stress and Bioresources Utilization for Sustainable Development
por: Shao, Hong-bo, et al.
Publicado: (2014)

ABioTrans: A Biostatistical Tool for Transcriptomics Analysis
por: Zou, Yutong, et al.
Publicado: (2019)

Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2
por: McInnes, Iain B, et al.
Publicado: (2019)

Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis
por: Montepaone, Monica, et al.
Publicado: (2014)

Ustekinumab-induced amelioration of both palmoplantar psoriasis and psoriatic glossitis
por: Tonini, Annalisa, et al.
Publicado: (2019)

Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden
por: Geale, Kirk, et al.
Publicado: (2020)

Ustekinumab-induced chronic lymphocytic leukemia in a patient with psoriatic arthritis
por: Gediz, Fusun, et al.
Publicado: (2021)

Corrigendum to: Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden
por: Geale, Kirk, et al.
Publicado: (2021)

Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce
por: De Marco, Gabriele, et al.
Publicado: (2023)

Multiple Lentigines Arising in Sites of Resolving Psoriatic Plaques after Treatment with Ustekinumab
por: Kim, Jeong Soo, et al.
Publicado: (2018)

Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
por: Helliwell, Philip S, et al.
Publicado: (2020)

The comparison of effectiveness of therapy with ustekinumab and etanercept in psoriatic patients during 48 weeks’ observation
por: Wcisło-Dziadecka, Dominika, et al.
Publicado: (2021)

H3ABioNet genomic medicine and microbiome data portals hackathon proceedings
por: Fadlelmola, Faisal M, et al.
Publicado: (2021)

Ustekinumab Treatment and Improvement of Physical Function and Health‐Related Quality of Life in Patients With Psoriatic Arthritis
por: Rahman, Proton, et al.
Publicado: (2016)

Correction to: H3ABioNet genomic medicine and microbiome data portals hackathon proceedings
Publicado: (2023)

Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study
por: Tillett, William, et al.
Publicado: (2023)

H3ABioNet computational metagenomics workshop in Mauritius: training to analyse microbial diversity for Africa
por: Baichoo, Shakuntala, et al.
Publicado: (2015)

Assessing computational genomics skills: Our experience in the H3ABioNet African bioinformatics network
por: Jongeneel, C. Victor, et al.
Publicado: (2017)

Organizing and running bioinformatics hackathons within Africa: The H3ABioNet cloud computing experience
por: Ahmed, Azza E., et al.
Publicado: (2019)

The H3ABioNet helpdesk: an online bioinformatics resource, enhancing Africa’s capacity for genomics research
por: Kumuthini, Judit, et al.
Publicado: (2019)

Role of clinical and biochemical inflammation in structural progression of patients with psoriatic arthritis
por: Borst, Carina, et al.
Publicado: (2021)

H3ABioNet, a sustainable pan-African bioinformatics network for human heredity and health in Africa
por: Mulder, Nicola J., et al.
Publicado: (2016)

Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials
por: Mease, Philip, et al.
Publicado: (2022)

Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA
por: Richette, Pascal, et al.
Publicado: (2023)

The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register
por: Jones, Gareth T., et al.
Publicado: (2021)

Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis
por: Kawalec, P., et al.
Publicado: (2017)

Designing a course model for distance-based online bioinformatics training in Africa: The H3ABioNet experience
por: Gurwitz, Kim T., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2qnq8164f9u1e6g5hvfp1tg2vq